RxDoctor Payments DataLook up a doctor →

Andrew Colhoun, MD

Urology · Richmond, VANPI 1396006961

Payments from drug & device makers

$19,019in general payments, 2019–2025

Across 820 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$3K
  • Dendreon Pharmaceuticals LLC$2K
  • Sumitomo Pharma America, Inc.$1K
  • AbbVie$1K
  • Johnson & Johnson$989
  • Urogen Pharma, Inc.$945
  • plus $10K from 49 others

What the payments were for

  • Speaking & faculty fees$790%
  • Food & beverage$18,91199%
  • Education$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,019 in reported general payments places this provider in the 80th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$494,321
Medicare patients
930
Services billed
20,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide20$267,691
XtandiEnzalutamide20$173,842
GemtesaVibegron104$85,812
MyrbetriqMirabegron116$83,570
OrgovyxRelugolix31$78,696
Solifenacin Succinate279$13,519
Silodosin71$8,154
Tamsulosin Hcl704$7,510
Mirabegron ErMirabegron11$5,260
Finasteride386$4,783
Tadalafil26$4,725
Testosterone Cypionate70$3,328
Methenamine Hippurate35$3,235
Alfuzosin Hcl ErAlfuzosin Hcl151$2,456
Tolterodine Tartrate ErTolterodine Tartrate17$2,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$989$267,69120 claims
Astellas Pharma US IncXtandi, Myrbetriq$559$257,412136 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$1,161$164,508135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 300 urology providers in Virginia.

Other urology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →